INKT (MiNK Therapeutics) Float Percentage Of Total Shares Outstanding : 25.42% (As of Mar. 22, 2025)

View and export this data going back to 2021. Start your Free Trial

What is MiNK Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, MiNK Therapeutics's float shares is 1.01 Mil. MiNK Therapeutics's total shares outstanding is 3.96 Mil. MiNK Therapeutics's float percentage of total shares outstanding is 25.42%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, MiNK Therapeutics's Insider Ownership is 80.48%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, MiNK Therapeutics's Institutional Ownership is 2.04%.

MiNK Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

MiNK Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	1.01	/	3.96
	=	25.42%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiNK Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

149 Fifth Avenue, Suite 500, New York, NY, USA, 10010

Website

https://www.minktherapeutics.com

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

Executives

Agenus Inc	10 percent owner	3 FORBES ROAD, LEXINGTON MA 02421
Garo H Armen	director	3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg	director
Brian Corvese	director	C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Christine M Klaskin	officer: Treasurer	3 FORBES ROAD, LEXINGTON MA 02421
Jennifer Buell	director, officer: See Remarks	3 FORBES ROAD, LEXINGTON MA 02421
Barbara Ryan	director	22 CAVRAY ROAD, NORWALK CT 06855
Walter Md Flamenbaum	director	3 FORBES ROAD, LEXINGTON MA 02421
John Baldoni	director	3 FORBES ROAD, LEXINGTON MA 02421
Peter Behner	director	3 FORBES ROAD, LEXINGTON MA 02421
Van Dijk Marcus Antonius	officer: Chief Technology Officer	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010